Clinical Trials Browser

Phase 2 × Active not recruiting × telisotuzumab vedotin × Clear all

NCT03539536 2025-11-05

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

270 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms